www.innocyto.com

InnoCyto Inc.

15375 Barranca Pkwy, Suite I-103
Irvine, CA 92618
Email: info@innocyto.com
Phone: 1-949-418-7543

Recombinant human TGFβ1 Protein

Catalog Number:	632401, 632402
Size:	20 μg, 100 μg
Target Name:	TGFb1, TGFB, transforming growth factor, TGF-Beta-1, Transforming Growth Factor Beta 1
Regulatory Status:	RUO

PRODUCT DETAILS

Application:	Bioassay
Format:	Lyophilized from sterile 100mM GLY, 10mM NaCl, pH 3.0
Expression Host:	Stable CHO
Species:	Human
accession number:	NP_000651.3
Sources:	A DNA sequence encoding the active form of human / rhesus / cynomolgus / canine TGFβ1 (NP_000651.3) (Ala 279-Ser 390) was expressed and purified. Human, Rhesus, cynomolgus and Canine TGFβ1 sequences are identical.
Molecular Weight:	The recombinant human / rhesus / cynomolgus / canine TGFβ1 consists of 112 amino acids and has a calculated molecular mass of 12.8 kDa. it migrates as an approximately 13 & 26 kDa band in reduced and non-reduced SDS-PAGE respectively, corresponding to the monomer and homodimer.
Affinity Tag:	None
Purity:	≥ 95 % as determined by SDS-PAGE
Endotoxin level:	< 1.0 EU per μg protein
Protein Concentration:	Lyophilized
Storage and Handling:	Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.

BACKGROUND INFORMATION

Human TGF-β1 (transforming growth factor beta 1) is a multifunctional cytokine that regulates cell proliferation, differentiation, migration, immune responses, extracellular-matrix production, wound healing, and tissue homeostasis. It is particularly important for controlling immune activity and maintaining normal tissue repair. TGF-β1 signals primarily through a receptor complex consisting of TGF-β receptor type II (TGFBR2) and type I (TGFBR1/ALK5), activating SMAD2/3 and other downstream pathways.

Structurally, mature human TGF-β1 is a 112-amino-acid polypeptide that forms a disulfide-linked homodimer of approximately 25 kDa. It has the characteristic cysteine-rich structure of the TGF-β superfamily, including a conserved cysteine-knot motif. TGF-β1 is synthesized as a larger precursor containing an N-terminal signal peptide, a latency-associated peptide (LAP), and the C-terminal

mature growth-factor domain. After processing, LAP remains associated with mature TGF-β1, maintaining it in an inactive latent complex.

The major ligands closely related to TGF-β1 are TGF-β2 and TGF-β3. TGF-β1 binds TGFBR2 and subsequently recruits TGFBR1, while the co-receptor betaglycan (TGFBR3) can modulate ligand presentation and signaling. TGF-β1 activity is normally tightly regulated because excessive or prolonged signaling can contribute to fibrosis, cancer progression, chronic inflammation, and abnormal tissue remodeling. In cancer, TGF-β1 can suppress immune responses and promote tumor invasion and metastasis, while excessive signaling in organs such as the lung, liver, kidney, and heart can promote fibrosis.

Because of these effects, TGF-β1 is an important therapeutic target. Approaches under investigation include neutralizing antibodies, ligand traps, inhibitors of TGFBR1 kinase activity, and strategies that prevent activation of latent TGF-β1. Such therapies are being studied particularly for cancer and fibrotic diseases. However, because TGF-β1 is essential for normal immune regulation and tissue repair, therapeutic inhibition must be carefully controlled to avoid disrupting beneficial physiological functions.

This product is supplied subject to the terms and conditions at www.innocyto.com/web/terms.php and may only be used as provided in the stated terms. Products are for Research Use Only.